Hemofiltration for neuroprotection in acute ischemic stroke

A prospective, pilot study

Dmitriy Viderman, Philip la Fleur, Federico Bilotta, Agzam Zhumadilov

Research output: Contribution to journalArticle

Abstract

Background: Hemofiltration reduces blood levels of cytokines, glutamate, and other substances that increase the risk of stroke-associated neurodegeneration. This study aimed to assess the safety and efficacy of hemofiltration in acute ischemic stroke patients. Methods: A total of 37 patients (mean age 56 ± 16 years) who had an ischemic stroke within the previous 12 hours were randomized to receive hemofiltration for 36 hours (n = 19) or standard treatment (n = 18). The primary outcome of interest was the occurrence of adverse events during the 28-day period following the stroke symptom onset. The secondary outcome was to assess the efficacy of hemofiltration in acute ischemic stroke. Results: Eighteen patients who received hemofiltration and 17 patients who received standard care completed the study. There were no cases of sepsis or infection at the hemofiltration cannula site, nor other hemofiltration-related complications. There was one case of fatal hemorrhagic transformation in each of the two groups. We failed to find any favorable effects on NIHSS scores at 7 days. However, we observed 17 patients (94%) with systemic inflammatory response syndrome in the control group and only 13 (68%) in the hemofiltration group. Conclusion: Hemofiltration appears to be safe in acute ischemic stroke patients, but we were unable to demonstrate its efficacy. However, for a definite conclusion on efficacy, a larger study with longer follow-up is required.

Original languageEnglish
JournalActa Neurologica Scandinavica
Early online dateDec 13 2018
DOIs
Publication statusE-pub ahead of print - Dec 13 2018

Fingerprint

Hemofiltration
Stroke
Prospective Studies
Neuroprotection
Systemic Inflammatory Response Syndrome
Glutamic Acid
Sepsis
Cytokines
Safety
Control Groups

Keywords

  • acute ischemic stroke
  • excitotoxicity
  • glutamate
  • hemofiltration
  • neuroprotection

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Hemofiltration for neuroprotection in acute ischemic stroke : A prospective, pilot study. / Viderman, Dmitriy; la Fleur, Philip; Bilotta, Federico; Zhumadilov, Agzam.

In: Acta Neurologica Scandinavica, 13.12.2018.

Research output: Contribution to journalArticle

@article{ebff29e4ae644801858723375dd603c2,
title = "Hemofiltration for neuroprotection in acute ischemic stroke: A prospective, pilot study",
abstract = "Background: Hemofiltration reduces blood levels of cytokines, glutamate, and other substances that increase the risk of stroke-associated neurodegeneration. This study aimed to assess the safety and efficacy of hemofiltration in acute ischemic stroke patients. Methods: A total of 37 patients (mean age 56 ± 16 years) who had an ischemic stroke within the previous 12 hours were randomized to receive hemofiltration for 36 hours (n = 19) or standard treatment (n = 18). The primary outcome of interest was the occurrence of adverse events during the 28-day period following the stroke symptom onset. The secondary outcome was to assess the efficacy of hemofiltration in acute ischemic stroke. Results: Eighteen patients who received hemofiltration and 17 patients who received standard care completed the study. There were no cases of sepsis or infection at the hemofiltration cannula site, nor other hemofiltration-related complications. There was one case of fatal hemorrhagic transformation in each of the two groups. We failed to find any favorable effects on NIHSS scores at 7 days. However, we observed 17 patients (94{\%}) with systemic inflammatory response syndrome in the control group and only 13 (68{\%}) in the hemofiltration group. Conclusion: Hemofiltration appears to be safe in acute ischemic stroke patients, but we were unable to demonstrate its efficacy. However, for a definite conclusion on efficacy, a larger study with longer follow-up is required.",
keywords = "acute ischemic stroke, excitotoxicity, glutamate, hemofiltration, neuroprotection",
author = "Dmitriy Viderman and {la Fleur}, Philip and Federico Bilotta and Agzam Zhumadilov",
note = "{\circledC} 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2018",
month = "12",
day = "13",
doi = "10.1111/ane.13060",
language = "English",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley Blackwell",

}

TY - JOUR

T1 - Hemofiltration for neuroprotection in acute ischemic stroke

T2 - A prospective, pilot study

AU - Viderman, Dmitriy

AU - la Fleur, Philip

AU - Bilotta, Federico

AU - Zhumadilov, Agzam

N1 - © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2018/12/13

Y1 - 2018/12/13

N2 - Background: Hemofiltration reduces blood levels of cytokines, glutamate, and other substances that increase the risk of stroke-associated neurodegeneration. This study aimed to assess the safety and efficacy of hemofiltration in acute ischemic stroke patients. Methods: A total of 37 patients (mean age 56 ± 16 years) who had an ischemic stroke within the previous 12 hours were randomized to receive hemofiltration for 36 hours (n = 19) or standard treatment (n = 18). The primary outcome of interest was the occurrence of adverse events during the 28-day period following the stroke symptom onset. The secondary outcome was to assess the efficacy of hemofiltration in acute ischemic stroke. Results: Eighteen patients who received hemofiltration and 17 patients who received standard care completed the study. There were no cases of sepsis or infection at the hemofiltration cannula site, nor other hemofiltration-related complications. There was one case of fatal hemorrhagic transformation in each of the two groups. We failed to find any favorable effects on NIHSS scores at 7 days. However, we observed 17 patients (94%) with systemic inflammatory response syndrome in the control group and only 13 (68%) in the hemofiltration group. Conclusion: Hemofiltration appears to be safe in acute ischemic stroke patients, but we were unable to demonstrate its efficacy. However, for a definite conclusion on efficacy, a larger study with longer follow-up is required.

AB - Background: Hemofiltration reduces blood levels of cytokines, glutamate, and other substances that increase the risk of stroke-associated neurodegeneration. This study aimed to assess the safety and efficacy of hemofiltration in acute ischemic stroke patients. Methods: A total of 37 patients (mean age 56 ± 16 years) who had an ischemic stroke within the previous 12 hours were randomized to receive hemofiltration for 36 hours (n = 19) or standard treatment (n = 18). The primary outcome of interest was the occurrence of adverse events during the 28-day period following the stroke symptom onset. The secondary outcome was to assess the efficacy of hemofiltration in acute ischemic stroke. Results: Eighteen patients who received hemofiltration and 17 patients who received standard care completed the study. There were no cases of sepsis or infection at the hemofiltration cannula site, nor other hemofiltration-related complications. There was one case of fatal hemorrhagic transformation in each of the two groups. We failed to find any favorable effects on NIHSS scores at 7 days. However, we observed 17 patients (94%) with systemic inflammatory response syndrome in the control group and only 13 (68%) in the hemofiltration group. Conclusion: Hemofiltration appears to be safe in acute ischemic stroke patients, but we were unable to demonstrate its efficacy. However, for a definite conclusion on efficacy, a larger study with longer follow-up is required.

KW - acute ischemic stroke

KW - excitotoxicity

KW - glutamate

KW - hemofiltration

KW - neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=85059137764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059137764&partnerID=8YFLogxK

U2 - 10.1111/ane.13060

DO - 10.1111/ane.13060

M3 - Article

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

ER -